Market cap
$2b
End-of-day close multiplied by current shares on issue.
RYM · NZX
Ryman Healthcare (RYM)
Healthcare / Retirement livingCovered: FY22 - FY267 published briefings
Ryman Healthcare is an NZX-listed healthcare / retirement living company. Its latest covered result is FY26, with FY22 - FY26 of source-backed result history on Annolyse.
Sections
Latest result
Latest metrics
FY26, released 26 May 2026
← Swipe to view more
| Metric | Value | Change |
|---|---|---|
| Revenue | $855.6m | ↑ +12.5% |
| EBITDAF | $88.3m | ↑ +94.1% |
| NPAT | -$171.3m | ↑ +60.8% |
| Operating cash flow | $334m | ↓ -18.6% |
| OCF / EBITDAF % | 378.2% | ↓ -523.4pp |
| ROE % | -4.2% | ↑ +6.1pp |
| PBT | -$177.6m | ↑ +17.5% |
| FCF pre-lease | $188.3m | ↑ +299.9% |
| FCF post-lease | $188.3m | ↑ +299.9% |
| Debtor days | 11 | ↑ +0.9% |
Source: latest published briefing (FY26, released 26 May 2026). Change compares against the prior equivalent period: FY25, released 29 May 2025.
Valuation
Valuation
Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.
Prices as at close, 18 September 2026
Price and market cap
The latest close and share count context for the market price.
i
Profitability multiples
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.17
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
10.71x
Market cap compared with recent free cash flow.
P/B
0.49x
Market value compared with latest reported equity.
Income and investment-company measures
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Price history
Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.
Share price
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Loading chart...
Chat
Ask about RYM
Ask follow-up questions about Ryman Healthcare's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Ask about RYM
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Financial history
Performance over time
The latest period is shown first.
← Swipe to view more
| Metric | FY2612 MONTHS26 May 2026 | HY266 MONTHS27 November 2025 | FY2512 MONTHS29 May 2025 | HY256 MONTHS28 November 2024 | HY246 MONTHS29 November 2023 | HY236 MONTHS18 November 2022 | FY2212 MONTHS17 June 2022 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | $855.6m | $413.8m | $760.7m | $366.3m | $323m | $274.2m | $508.8m | Chart |
| Revenue growth % | 12.5% | 13.0% | 10.3% | 13.4% | 17.8%Outside range high revenue growth. 17.8%; 3-period range 10.6% to 13.4%. Revenue growth: 17.8%, above normal range; 3-period mean 12.3%, range 10.6%-13.4%. | 10.6%Outside range low revenue growth. 10.6%; 3-period range 13% to 17.8%. Revenue growth: 10.6%, below normal range; 3-period mean 14.7%, range 13.0%-17.8%. | 11.6% | Chart
|
| EBITDAF | $88.3m | $40.1m | $45.5m | — | $146.3m | — | — | Chart |
| EBITDAF margin % | 10.3% | 9.7% | 6.0% | — | 45.3% | — | — | Chart |
| PBT | -$177.6m | -$40.2m | -$215.4m | $174.8m | $143.4m | $217.3m | $722.1m | Chart |
| PBT growth % | — | — | — | 21.9%Outside range high pbt growth. 21.9%; 3-period range -123% to -20.8%. PBT growth: 21.9%, above normal range; 3-period mean -59.3%, range -123.0%--20.8%. | -34.0% | -20.8% | 75.9% | Chart
|
| NPAT | -$171.3m | -$45.2m | -$436.8m | $94.4m | $186.7m | $194m | $692.9m | Chart |
| NPAT growth % | — | — | — | -49.4% | -3.8%Outside range high npat growth. -3.8%; 3-period range -147.9% to -31.1%. NPAT growth: -3.8%, above normal range; 3-period mean -76.1%, range -147.9%--31.1%. | -31.1% | 63.8% | Chart
|
| Operating cash flow | $334m | $172.9m | $410.3m | $282.8m | $337.9m | $243.7m | $586m | Chart |
| OCF / EBITDAF % | 378.2% | 431.0% | 901.6% | — | 231.0% | — | — | Chart |
| FCF pre-lease | $188.3m | $56.2m | -$94.2m | -$52.5m | -$158.4m | $51.8m | $301.7m | Chart |
| FCF post-lease | $188.3m | $56.2m | -$94.2m | -$52.5m | -$158.4m | — | — | Chart |
| DPS | — | — | — | — | 0.0c | 8.8c | — | Chart |
| Payout ratio vs NPAT % | — | — | — | — | — | 22.7% | — | — |
| ROE % | -4.2% | -1.1%Outside range low roe. -1.1%; 3-period range 2.2% to 10.7%. ROE: -1.1%, below normal range; 3-period mean 5.6%, range 2.2%-10.7%. | -10.3% | 2.2% | 3.8% | 10.7%Outside range high roe. 10.7%; 3-period range -1.1% to 3.8%. ROE: 10.7%, above normal range; 3-period mean 1.6%, range -1.1%-3.8%. | 20.2% | Chart
|
| Debtor days | 11 | 10Outside range low debtor days. 10d; 3-period range 11d to 525d. Debtor days: 10.4 days, below normal range; 3-period mean 306.0 days, range 10.6 days-525.4 days. | 11 | 11 | 382 | 525Outside range high debtor days. 525d; 3-period range 10d to 382d. Debtor days: 525.4 days, above normal range; 3-period mean 134.3 days, range 10.4 days-381.9 days. | 470 | Chart
|
| Inventory days | n/m | n/m | n/m | 1 | 5 | 15Outside range high inventory days. 15d; 3-period range 0d to 5d. Inventory days: 15.4 days, above normal range; 3-period mean 1.9 days, range 0.0 days-4.7 days. | 19 | Chart
|
| Total assets | $12.3b | $12.1b | $12.1b | $12.8b | $13.1b | $12b | $11b | Chart |
Reference: annolyse.ai/companies/rym
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
Filing-only history charts
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Revenue
Reported revenue across covered periods.
Loading chart...
Revenue growth
Like-period revenue growth where comparable.
Loading chart...
- HY23 RYM HY: Outside range low revenue growth. 10.6%; 3-period range 13% to 17.8%. Revenue growth: 10.6%, below normal range; 3-period mean 14.7%, range 13.0%-17.8%.
- HY24 RYM HY: Outside range high revenue growth. 17.8%; 3-period range 10.6% to 13.4%. Revenue growth: 17.8%, above normal range; 3-period mean 12.3%, range 10.6%-13.4%.
EBITDA-equivalent
Company-specific earnings measure where disclosed.
Loading chart...
EBITDA margin
EBITDA-equivalent margin where revenue and earnings are source-backed.
Loading chart...
NPAT
Statutory profit after tax.
Loading chart...
Operating cash flow
Cash generated from operations.
Loading chart...
More financial metrics
Additional filing-backed metrics for this company. Each point links to the relevant published briefing.
OCF / EBITDA
Cash conversion against earnings.
Loading chart...
FCF pre-lease
Operating cash flow less capex before leases.
Loading chart...
FCF post-lease
Free cash flow after lease payments where available.
Loading chart...
ROE
Return on equity.
Loading chart...
- HY23 RYM HY: Outside range high roe. 10.7%; 3-period range -1.1% to 3.8%. ROE: 10.7%, above normal range; 3-period mean 1.6%, range -1.1%-3.8%.
- HY26 RYM HY: Outside range low roe. -1.1%; 3-period range 2.2% to 10.7%. ROE: -1.1%, below normal range; 3-period mean 5.6%, range 2.2%-10.7%.
DPS
Dividend per share declared for the period.
Loading chart...
Payout ratio
Dividend payout against statutory NPAT.
Loading chart...
Debtor days
Receivables days where the working-capital inputs are source-backed.
Loading chart...
- HY23 RYM HY: Outside range high debtor days. 525d; 3-period range 10d to 382d. Debtor days: 525.4 days, above normal range; 3-period mean 134.3 days, range 10.4 days-381.9 days.
- HY26 RYM HY: Outside range low debtor days. 10d; 3-period range 11d to 525d. Debtor days: 10.4 days, below normal range; 3-period mean 306.0 days, range 10.6 days-525.4 days.
Inventory days
Inventory days where the working-capital inputs are source-backed.
Loading chart...
- HY23 RYM HY: Outside range high inventory days. 15d; 3-period range 0d to 5d. Inventory days: 15.4 days, above normal range; 3-period mean 1.9 days, range 0.0 days-4.7 days.
Operating working-capital movement
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
Loading chart...
The setup & the reality
HY26 → FY26 Follow-through
The latest result is checked against what the prior briefing said to watch.
Historical setup
What HY26 said to watch
Previous analysisHY26Result releasedAnnolyse analysis published
From PBT collapsed 123% to a NZ$40.2m loss as debt fell NZ$928m
No forward target was supplied. HY25 represented 48.1% of FY25 revenue, but FY25 NPAT of -NZ$436.8m was dominated by an implied second-half fair-value swing of roughly -NZ$531.2m. That makes the FY26 NPAT shape highly contingent on property revaluations rather than trading.
Management cited cost-out tracking ahead of expectations, a refreshed sales strategy, and "significant uplift in average DMF on ORA sales". Those points speak to EBITDAF and cash settlements; none of them resolve the second-half fair-value risk.
Open questions
Open questions from HY26
- Is the 86.4% reduction in trade debtors a one-off collection tied to the balance sheet reset, or a sustainable change in receivables behaviour?
- What is the expected path of property fair-value movements in 2H26, given FY25's second half drove an implied -NZ$531.2m NPAT swing?
- How much of the cost-out programme has been delivered in the HY26 EBITDAF figure, and what is the run-rate target?
- What is the post-reset target leverage range, given EBITDAF of NZ$40.1m sits against NZ$1.65b of net debt?
- Will the refreshed sales strategy and higher DMF on ORA sales translate into accelerating cash settlements in 2H26 without further working-capital tailwinds?
This briefing cannot assess the full-year fair-value outcome or the durability of the receivables compression without additional disclosure.
Latest result sources
Primary issuer documents used for the FY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.
Current period
Ryman Healthcare Limited - Announcement Numbers - 31 March 2026
FY26 / results announcementRyman Healthcare Limited - Financial Statements - 31 March 2026
FY26 / financial reportRyman Healthcare Limited - Results Presentation - 31 March 2026
FY26 / results presentationPrior comparable period
Ryman Healthcare Limited - Consolidated Financial Statements - 31 March 2025
FY25 / financial reportRyman Healthcare Limited - NZX Release - 31 March 2025
FY25 / results announcementRyman Healthcare Limited - NZX Release - 31 March 2025
FY25 / results releaseRyman Healthcare Limited - Results Presentation - 31 March 2025
FY25 / results presentationInterim context
Ryman Healthcare Limited - Interim Financial Statements - 30 September 2025
HY26 / financial reportRyman Healthcare Limited - Media Release - 30 September 2025
HY26 / results announcementRyman Healthcare Limited - Media Release - 30 September 2025
HY26 / media releaseRyman Healthcare Limited - Results Presentation - 30 September 2025
HY26 / results presentationRelease context
2026 Investor Day Recording
FY26 / commentaryRyman Healthcare Limited - Investor Day Presentation
FY26 / commentaryRyman Healthcare Limited - 2025 Annual Meeting NZX Release
HY26 / commentaryRyman Healthcare Limited - 2025 Annual Meeting voting results
HY26 / commentaryPeer context
Retirement living comparison set
These companies share the same curated sub-sector label. Their reporting definitions can still differ, so compare the underlying measures before ranking them.
Archive
Briefing archive
The full chronological archive contains every published result briefing.
FY26 · Released 26 May 2026
Free cash flow swings to +NZ$188m as EBITDAF nearly doubles
Operating momentum is real but Ryman remains loss-making at the PBT line, and the FCF swing is partly capex-driven rather than purely earnings-led.
Read briefing
HY26 · Released 27 November 2025
PBT collapsed 123% to a NZ$40.2m loss as debt fell NZ$928m
Maiden NZ$56.2m FCF and the balance sheet reset frame the upside, but a NZ$152.7m receivables release flatters the cash result.
Read briefing
FY25 · Released 29 May 2025
EBITDAF tripled to $45.5m but NPAT loss widened to -$436.8m
Operating recovery is overshadowed by a capex surge to 70.4% of revenue and a -$94.2m free cash outflow.
Read briefing
HY25 · Released 28 November 2024
PBT up 21.9% but NPAT fell 49.4% on a tax-rate flip
A tax line that flipped from +30.2% to -46.0% drove the NPAT divergence while pre-lease free cash flow stayed below the historical range at -$52.5m.
Read briefing
HY24 · Released 29 November 2023
Dividend suspended as FCF stays $158.4m negative, PBT falls 34%
Headline NPAT declines just 3.8% on a 30.2% tax credit, but underlying profit is flat and pre-lease cash flow sits well below the historical range.
Read briefing
HY23 · Released 18 November 2022
NZ$281m working-capital build cut pre-lease FCF to NZ$51.8m as NPAT fell 31%
Underlying profit rose 44.8% but reported NPAT fell 31.1% as receivables expanded and capex jumped 56%, draining cash flow despite revenue growth.
Read briefing
Get notified when RYM publishes
Get the next Ryman Healthcare result briefing and five-year history updates by email.